Trials / Unknown
UnknownNCT00923663
Trial of Lenalidomide in Patients With Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) Type
Phase II Trial of Lenalidomide in Patients With Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) Type
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 16 (estimated)
- Sponsor
- Medical University of Vienna · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The activity of monotherapy with Lenalidomide will be evaluated in patients with lymphoma of the mucosa associated lymphoid tissue (MALT).
Detailed description
The primary objective of the study is to evaluate the clinical potential of Lenalidomide to induce objective/histologic responses in patients with MALT lymphoma. The secondary objectives are to evaluate the safety of Lenalidomide in this patient population and to evaluate the impact of Lenalidomide on progression free survival.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lenalidomide | 25 mg Lenalidomide p.o. daily for 21 days |
Timeline
- Start date
- 2009-07-01
- Primary completion
- 2011-06-01
- Completion
- 2011-06-01
- First posted
- 2009-06-18
- Last updated
- 2010-09-28
Locations
1 site across 1 country: Austria
Source: ClinicalTrials.gov record NCT00923663. Inclusion in this directory is not an endorsement.